Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
AUPH Stock Chart & Stats
$14.15
$0.10(1.19%)
At close: 4:00 PM EST
$14.15
$0.10(1.19%)
Day’s Range― - ―
52-Week Range$6.83 - $16.54
Previous CloseN/A
Volume460.34K
Average Volume (3M)848.13K
Market Cap
$1.88B
Enterprise Value$1.98B
Total Cash (Recent Filing)$398.00M
Total Debt (Recent Filing)$74.81M
Price to Earnings (P/E)6.8
Beta0.42
Next Earnings
Apr 30, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.53
Shares Outstanding132,970,980
10 Day Avg. Volume903,692
30 Day Avg. Volume848,130
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.69
Price to Sales (P/S)7.57
P/FCF Ratio15.83
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue6.99
Enterprise Value/Gross Profit7.90
Enterprise Value/Ebitda13.90
Forecast
1Y Price Target
$16.00Price Target Upside13.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.94
Revenue Forecast (FY)$326.80M
Bulls Say, Bears Say
Bulls Say
Commercial MomentumLupkynis revenue growth that has exceeded analyst expectations and management projections of continued sales strength despite a smaller sales force indicates growing market acceptance and commercial resilience.
Guideline-driven AdoptionUpdated lupus nephritis and rheumatology guidelines that emphasize proactive proteinuria screening and support calcineurin inhibitors are expanding the diagnosed patient pool and increasing clinician use of Lupkynis.
Pipeline CatalystClarification of aritinercept's targeted indication and the start of clinical studies, combined with early signals of robust immunoglobulin reductions and a monthly dosing profile, could unlock meaningful pipeline value if study results are favorable.
Bears Say
Competitive PressureApproval of a rival lupus nephritis therapy increases competitive pressure and could constrain Lupkynis market share growth despite its faster onset-of-action characteristics.
Patent And Exclusivity RiskMultiple generic challenges to the company's key dosing patent create uncertainty around long-term exclusivity and raise the risk of future sales erosion if challenges succeed.
Rising Operating CostsInitiation of new clinical trials and ongoing patent litigation are expected to raise operating expenses, which may pressure near-term profitability and cash flow.
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $6.83 and its highest was $16.54 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $1.88B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Apr 30, 2026 which is in 56 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Aurinia Pharmaceuticals released its earnings results on Feb 26, 2026. The company reported $1.53 earnings per share for the quarter, beating the consensus estimate of $0.217 by $1.313.
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate is 0.2.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 132,970,980 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Aurinia Pharmaceuticals reported an EPS of $1.53 in its last earnings report, beating expectations of $0.217. Following the earnings report the stock price went down -3.188%.
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurinia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (13.07% Upside)
$16.00 (13.07% Upside)
Blogger Sentiment
Bullish
AUPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
77.31%
12-Months-Change
Fundamentals
Return on Equity
59.91%
Trailing 12-Months
Asset Growth
39.94%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
AUPH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.View all AUPH earnings summariesAUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$16.00
▲(13.07% Upside)
Technical Analysis
Ownership Overview
11.41% Insiders
4.49% Mutual Funds
4.04% Other Institutional Investors
72.89% Public Companies and Individual Investors